Literature DB >> 7523287

Studies on the thymus of non-obese diabetic (NOD) mice: effect of transgene expression.

L A O'Reilly1, D Healey, E Simpson, P Chandler, T Lund, M A Ritter, A Cooke.   

Abstract

The non-obese diabetic (NOD) mouse is a good model of insulin-dependent diabetes mellitus. Autoreactive T cells may play a fundamental role in disease initiation in this model, while disregulation of such cells may result from an abnormal thymic microenvironment. Diabetes is prevented in NOD mice by direct introduction of an E alpha d transgene (NOD-E) or a modified I-A beta chain of NOD origin (NOD-PRO or NOD-ASP). To investigate if disease pathology in NOD mice, protection from disease in transgenic NOD-E and NOD-PRO and partial protection from disease in NOD-ASP can be attributed to alterations in the thymic microenvironment, immunohistochemical and flow cytometric analysis of the thymi of these mouse strains was studied. Thymi from NOD and NOD-E mice showed a progressive increase in thymic B-cell percentage from 12 weeks of age. This was accompanied by a concomitant loss in thymic epithelial cells with the appearance of large epithelial-free areas mainly at the corticomedullary junction, which increased in size and number with age and contained the B-cell clusters. Such thymic B cells did not express CD5 and were absent in CBA, NOD-ASP and NOD-PRO mice as were the epithelial cell-free spaces, even at 5 months of age. Therefore the mechanisms of disease protection in the transgenic NOD-E and NOD-ASP/NOD-PRO mice may differ if these thymic abnormalities are related to disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523287      PMCID: PMC1414832     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  62 in total

1.  Development and physiology of Ly-1 B and its human homolog, Leu-1 B.

Authors:  R R Hardy; K Hayakawa
Journal:  Immunol Rev       Date:  1986-10       Impact factor: 12.988

2.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

3.  T-cell repertoire.

Authors: 
Journal:  Immunol Rev       Date:  1988-01       Impact factor: 12.988

4.  T cell tolerance by clonal elimination in the thymus.

Authors:  J W Kappler; N Roehm; P Marrack
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

5.  The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique.

Authors:  H Acha-Orbea; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

6.  Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice.

Authors:  T Koike; Y Itoh; T Ishii; I Ito; K Takabayashi; N Maruyama; H Tomioka; S Yoshida
Journal:  Diabetes       Date:  1987-04       Impact factor: 9.461

7.  Cell surface appearance of unexpected host MHC determinants on thymocytes from radiation bone marrow chimeras.

Authors:  S O Sharrow; B J Mathieson; A Singer
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

8.  Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice.

Authors:  H Nishimoto; H Kikutani; K Yamamura; T Kishimoto
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

9.  Compartmentalization of MHC class II gene expression in transgenic mice.

Authors:  W van Ewijk; Y Ron; J Monaco; J Kappler; P Marrack; M Le Meur; P Gerlinger; B Durand; C Benoist; D Mathis
Journal:  Cell       Date:  1988-05-06       Impact factor: 41.582

10.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Genetic analysis of type 1 diabetes: embryonic stem cells as new tools to unlock biological mechanisms in type 1 diabetes.

Authors:  Nick Holmes; Anne Cooke
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.

Authors:  Xuezhi Dai; Richard G James; Tania Habib; Swati Singh; Shaun Jackson; Socheath Khim; Randall T Moon; Denny Liggitt; Alejandro Wolf-Yadlin; Jane H Buckner; David J Rawlings
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

3.  Complete diabetes protection despite delayed thymic tolerance in NOD8.3 TCR transgenic mice due to antigen-induced extrathymic deletion of T cells.

Authors:  Balasubramanian Krishnamurthy; Jonathan Chee; Gaurang Jhala; Stacey Fynch; Kate L Graham; Pere Santamaria; Grant Morahan; Janette Allison; David Izon; Helen E Thomas; Thomas W H Kay
Journal:  Diabetes       Date:  2011-12-21       Impact factor: 9.461

4.  Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model.

Authors:  David Baker; Erik Nutma; Helen O'Shea; Anne Cooke; Jacqueline M Orian; Sandra Amor
Journal:  Ann Clin Transl Neurol       Date:  2019-07-15       Impact factor: 4.511

Review 5.  Thymic B Cells as a New Player in the Type 1 Diabetes Response.

Authors:  Richard B Greaves; Dawei Chen; E Allison Green
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

Review 6.  Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity.

Authors:  Hugh McDevitt; Sibyl Munson; Rachel Ettinger; Ava Wu
Journal:  Arthritis Res       Date:  2002-05-09

7.  Peripheral Autoimmune Regulator Induces Exhaustion of CD4+ and CD8+ Effector T Cells to Attenuate Autoimmune Diabetes in Non-Obese Diabetic Mice.

Authors:  Divakar Kulshrestha; Li-Tzu Yeh; Ming-Wei Chien; Feng-Cheng Chou; Huey-Kang Sytwu
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

8.  Thymic B Cell-Mediated Attack of Thymic Stroma Precedes Type 1 Diabetes Development.

Authors:  Ana Isabel Pinto; Jennifer Smith; Miriam R Kissack; Karen G Hogg; E Allison Green
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.